Video
Dr. Reardon on Nivolumab/Ipilimumab in Glioblastoma
Author(s):
David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).
David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).
The CheckMate-143 trial is the first to show maturing data of the efficacy of checkpoint inhibitors in patients with recurrent GBM, with cohorts that examined nivolumab monotherapy as well as nivolumab combined with ipilimumab. In the combination cohort, dosage was 3 mg/kg of ipilimumab and 1 mg/kg of nivolumab. However, patients in the combination arm had a fair amount of grade 3/4 toxicities, Reardon added.
Following these reports, the study was amended to have an adjusted dosing schedule of 1 mg/kg of ipilimumab and 3 mg/kg of nivolumab. Results showed that the safety profile of the adjusted schedule was significantly improved, Reardon said.
<<<
